TY - JOUR
T1 - ProtLID, a Residue-Based Pharmacophore Approach to Identify Cognate Protein Ligands in the Immunoglobulin Superfamily
AU - Yap, Eng Hui
AU - Fiser, Andras
N1 - Funding Information:
This work was supported by NIH grant R01 GM118709 , and the Extreme Science and Engineering Discovery Environment (XSEDE) project ( NSF grant ACI-1053575 ).
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/12/6
Y1 - 2016/12/6
N2 - Members of the extracellular immunoglobulin superfamily (IgSF) play a key role in immune regulation through the control of the co-stimulatory pathway, and have emerged as potent drug targets in cancers, infectious diseases, and autoimmunity. Despite the difficult experimental access to this class of proteins, single structures of ectodomains of IgSF proteins are solved with regularity. However, the most biologically critical challenge for this class of proteins is the identification of their cognate ligands that communicate intercellular signals. We describe a conceptually novel method, protein-ligand interface design (ProtLID), to identify cognate ligands from a subproteome for a given target receptor protein. ProtLID designs an optimal protein interface for a given receptor by running extensive molecular dynamics simulations of single-residue probes. The type and location of residue preferences establish a residue-based pharmacophore, which is subsequently used to find potential matches among candidate ligands within a subproteome.
AB - Members of the extracellular immunoglobulin superfamily (IgSF) play a key role in immune regulation through the control of the co-stimulatory pathway, and have emerged as potent drug targets in cancers, infectious diseases, and autoimmunity. Despite the difficult experimental access to this class of proteins, single structures of ectodomains of IgSF proteins are solved with regularity. However, the most biologically critical challenge for this class of proteins is the identification of their cognate ligands that communicate intercellular signals. We describe a conceptually novel method, protein-ligand interface design (ProtLID), to identify cognate ligands from a subproteome for a given target receptor protein. ProtLID designs an optimal protein interface for a given receptor by running extensive molecular dynamics simulations of single-residue probes. The type and location of residue preferences establish a residue-based pharmacophore, which is subsequently used to find potential matches among candidate ligands within a subproteome.
KW - ProtLID
KW - Protein ligand interface design
KW - immunoglobulin superfamily
KW - receptor-ligand identification
UR - http://www.scopus.com/inward/record.url?scp=85002590581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002590581&partnerID=8YFLogxK
U2 - 10.1016/j.str.2016.10.012
DO - 10.1016/j.str.2016.10.012
M3 - Article
C2 - 27889206
AN - SCOPUS:85002590581
SN - 0969-2126
VL - 24
SP - 2217
EP - 2226
JO - Structure
JF - Structure
IS - 12
ER -